Which One to Endorse Among the Multitude of Lipid Guidelines?

Dyslipidemia is the major risk factor for atherosclerotic cardiovascular diseases. A multitude of lipid guidelines exist, with several controversies, and the best approach in dyslipidemia management is not clear. The tools and lipoproteins used for risk assessment, whether to use a treatment target...

Descripción completa

Detalles Bibliográficos
Autor principal: Sonmez, Alper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2015
Materias:
Cardiovascular Risk Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819059/
https://www.ncbi.nlm.nih.gov/pubmed/29632564
http://dx.doi.org/10.17925/EE.2015.11.01.32
_version_ 1783301130778836992
author Sonmez, Alper
author_facet Sonmez, Alper
author_sort Sonmez, Alper
collection PubMed
description Dyslipidemia is the major risk factor for atherosclerotic cardiovascular diseases. A multitude of lipid guidelines exist, with several controversies, and the best approach in dyslipidemia management is not clear. The tools and lipoproteins used for risk assessment, whether to use a treatment target and implementing drugs other than statins are all controversial points. Until the time for the publication of an agreeable lipid guideline, physicians should choose their way by considering the advantages and disadvantages of the existing guidelines.
format Online
Article
Text
id pubmed-5819059
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Touch Medical Media
record_format MEDLINE/PubMed
spelling pubmed-58190592018-04-09 Which One to Endorse Among the Multitude of Lipid Guidelines? Sonmez, Alper Eur Endocrinol Cardiovascular Risk Editorial Dyslipidemia is the major risk factor for atherosclerotic cardiovascular diseases. A multitude of lipid guidelines exist, with several controversies, and the best approach in dyslipidemia management is not clear. The tools and lipoproteins used for risk assessment, whether to use a treatment target and implementing drugs other than statins are all controversial points. Until the time for the publication of an agreeable lipid guideline, physicians should choose their way by considering the advantages and disadvantages of the existing guidelines. Touch Medical Media 2015-04 2015-04-11 /pmc/articles/PMC5819059/ /pubmed/29632564 http://dx.doi.org/10.17925/EE.2015.11.01.32 Text en © The Author(s) 2015 http://creativecommons.org/licenses/by/2.5/ This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
spellingShingle Cardiovascular Risk Editorial
Sonmez, Alper
Which One to Endorse Among the Multitude of Lipid Guidelines?
title Which One to Endorse Among the Multitude of Lipid Guidelines?
title_full Which One to Endorse Among the Multitude of Lipid Guidelines?
title_fullStr Which One to Endorse Among the Multitude of Lipid Guidelines?
title_full_unstemmed Which One to Endorse Among the Multitude of Lipid Guidelines?
title_short Which One to Endorse Among the Multitude of Lipid Guidelines?
title_sort which one to endorse among the multitude of lipid guidelines?
topic Cardiovascular Risk Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819059/
https://www.ncbi.nlm.nih.gov/pubmed/29632564
http://dx.doi.org/10.17925/EE.2015.11.01.32
work_keys_str_mv AT sonmezalper whichonetoendorseamongthemultitudeoflipidguidelines

Ejemplares similares